Comparative Pharmacology
Head-to-head clinical analysis: BYFAVO versus PAXIPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYFAVO versus PAXIPAM.
BYFAVO vs PAXIPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective adenosine A2A receptor antagonist; promotes wakefulness by blocking the inhibitory effects of adenosine on arousal-promoting neurons in the brain.
PAXIPAM (flurazepam) is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and producing CNS depression.
For induction and maintenance of general anesthesia: 0.3 mg/kg intravenously over 30 seconds, followed by an infusion of 1.5 mg/kg/hour adjusted to effect. Additional boluses of 0.075 mg/kg may be given as needed.
5-10 mg orally every 8-12 hours as needed; maximum 40 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours; clinical context: requires continuous infusion for sustained effect, as rapid clearance may lead to loss of efficacy.
Terminal elimination half-life is 30-40 hours in healthy adults; prolonged in elderly and hepatic impairment.
Renal excretion accounts for approximately 90% of the administered dose, with <5% as unchanged drug. Biliary/fecal elimination is minimal (<5%).
Renal excretion of unchanged drug and glucuronide metabolites accounts for 60-70%; fecal excretion accounts for 20-30%.
Category C
Category C
Benzodiazepine
Benzodiazepine